GENESIS MEDTECH UNVEILS NEW REVOLUTIONARY MEDTECH CAMPUS
New campus combines R&D, manufacturing, and training with the latest state-of-art facilities Brings innovation to next-level integration with medical professionals Expected to reach industrial-scale production levels with an output value of over 10 billion RMB (approximately US$1.38 billion) in three to five years SINGAPORE, Nov. 14, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis MedTech or Group)...
Akeso’s Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China
AK112 has now been granted three Breakthrough Therapy Designations for NSCLC The only drug candidate granted Breakthrough Therapy Designation for I-O Resistance NSCLC in China HONG KONG, Nov. 14, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") announced that the Center for Drug Evaluation (CDE) of the China National...
SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969
State-run financing to provide two-year support of Phase 1 research for oncology candidate, SKL27969, for the potential treatment of advanced solid tumors SK Biopharmaceuticals to present preclinical data on oncology candidate, SKL27969, at Society for Neuro-Oncology Conference PANGYO, South Korea, Nov. 14, 2022 /PRNewswire/ -- SK Biopharmaceuticals, a global innovative pharmaceutical company,...
Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting
ROCKVILLE,M.D. and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today presented the updated results of IBI351 (GFH925) (KRASG12C inhibitor) from a phase Ia clinical trial (NCT05005234) at the 2022 Chinese...
Telix Acquires Optimal Tracers
MELBOURNE, Australia and INDIANAPOLIS, Ind., Nov. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in...
New Report Finds over 90% of Australian Women Suffer from Period Related Symptoms
SYDNEY, Nov. 14, 2022 /PRNewswire/ -- A YouGov survey conducted by Australia's first ever period-symptom relief range, The Fix, has revealed over nine in ten (93%) of Australian women aged 16 to 50 experience period symptoms in a typical month with the most common symptoms being cramps/pain (73%), mood changes (69%) and fatigue (61%). The Fix founders, Kate Everitt...
Fullerton Health Medical Centre for Migrant Workers at Gul Circle Opens in Tuas
Catering to the Healthcare Needs of Migrant Workers Under the Primary Care Plan SINGAPORE, Nov. 12, 2022 /PRNewswire/ -- Fullerton Health Group (FHG) marked a major milestone by opening the doors to a new Medical Centre. Migrant Workers (MWs) residing in the West can seek medical attention at FHG's new medical facility located...
Treadwell Therapeutics Announces A Presentation at the 2022 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor
NEW YORK, Nov. 11, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines cancer, today announced a presentation for CFI-402411, an oral, first-in-class inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), a negative regulator of immune cell activation, at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting being held virtually and in-person from November 8-12, 2022 at the Boston...
INDUSTRY INNOVATION: AI SMILE Smart Tracking Case debut worldwide developed by Weiyun AI & Robotics Group
SHANGHAI, Nov. 11, 2022 /PRNewswire/ -- In last few decades, experts have been constantly discussing the future trend of AI application in medical scenarios: how to use AI as the underlying technology but actually transform the medical experiences of every individuals? Recently, Weiyun AI & Robotics Group, an internationally renowned industrial AI group company, once again got a full...
Telix to Present at Jefferies London Healthcare Conference 2022
MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that Dr Christian Behrenbruch, Group CEO and Managing Director, will be presenting at the Jefferies London Healthcare Conference 2022. The presentation will take...
